MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Country |
 Niderland |
IPO year |
2016 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
64.2 M |
Market Cap[1] |
$ 5.78 B |
EBITDA (LTM) |
$ -205 M |
P/E (LTM) |
- |
P/S (LTM) |
97.57 |
EPS (LTM) |
-6.35 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Anavex Life Sciences Corp.
AVXL
|
$ 3.02 | 1.0 % | $ 258 M | Nasdaq Capital Market |  USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
BioNTech SE
BNTX
|
$ 90.9 | -0.31 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
BioLineRx Ltd.
BLRX
|
$ 2.34 | 5.72 % | $ 908 M | Nasdaq Capital Market |  Israel |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Codexis
CDXS
|
$ 1.93 | 6.04 % | $ 168 M | Nasdaq Global Select Market | USA |
 |
Cerus Corporation
CERS
|
$ 1.9 | 1.88 % | $ 362 M | Nasdaq Global Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Cullinan Management
CGEM
|
$ 15.2 | 5.34 % | $ 916 M | Nasdaq Global Select Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.69 | -2.31 % | $ 198 M | Nasdaq Global Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 0.46 | -13.46 % | $ 5.27 M | Nasdaq Capital Market | Israel |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.11 | -0.48 % | $ 439 M | Nasdaq Global Market | USA |
 |
CNS Pharmaceuticals
CNSP
|
$ 2.27 | 0.39 % | $ 1.01 M | Nasdaq Capital Market | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 24.91 | 0.89 % | $ 3.05 B | Nasdaq Capital Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 8.3 | 3.36 % | $ 227 M | Nasdaq Global Market,SPB | Israel |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 10.37 | 1.97 % | $ 138 M | Nasdaq Global Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.6 | 0.95 % | $ 107 M | Nasdaq Capital Market | USA |
 |
Curis
CRIS
|
$ 0.53 | -3.64 % | $ 6.98 M | Nasdaq Global Market | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 38.09 | 2.31 % | $ 3.58 B | Nasdaq Global Select Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 49.43 | -0.17 % | $ 4.44 B | Nasdaq Global Market,SPB |  Schweiz |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
CytomX Therapeutics
CTMX
|
$ 4.41 | -3.4 % | $ 608 M | Nasdaq Global Select Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.87 | 1.26 % | $ 5.85 M | Nasdaq Capital Market | USA |
 |
Cue Biopharma
CUE
|
$ 0.17 | -7.12 % | $ 16.1 M | Nasdaq Capital Market,SPB | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Celldex Therapeutics
CLDX
|
$ 31.43 | 1.18 % | $ 2.09 B | Nasdaq Global Select Market | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 4.34 | -29.51 % | $ 10.9 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.